The therapeutic use of inhaled nitric oxide is based on its ability to achieve potent and sustained pulmonary vasodilation without significantly decreasing systemic vascular tone.
Linde Healthcare has developed a complete solution, INOmax Therapy, for the delivery of inhaled nitric oxide. Our solution integrates a dedicated system for administration, gas calibration, treatment recording, customer training and service support to ensure the most effective results with maximum patient safety. The delivery device INOvent fits every sort of ventilatory support mode and enables constant monitoring of delivered nitric oxide, oxygen and nitrogen dioxide.
In conjunction with ventilatory support and other appropriate agents, INOmax is indicated for the treatment of newborns >= 34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation.
You can find out more on our data protection information.